Novel Drug May Improve Daily Activities in ET: Phase 3 Trial

1 source1 article First seen 1 day ago Updated 1 day ago United States Truth score 38

Save Like Comments Compare coverage

Summary

Ulixacaltamide is associated with significantly greater improvement than placebo in all 12 activities of daily living domains assessed in patients with essential tremor in new research.

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 1 day ago
Novel Drug May Improve Daily Activities in ET: Phase 3 Trial
Ulixacaltamide is associated with significantly greater improvement than placebo in all 12 activities of daily living domains assessed in patients with essential tremor in new research.

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

Filter the stories

Sources Ratings and details

Novel Drug May Improve Daily Activities in ET: Phase 3 Trial

Summary

Who is covering this

Comments